Basic Latisse Information

• INN (International Nonproprietary Name): Bimatoprost.
• Brand Names Available In Australia: Lumigan, Latisse, Careprost; Latisse may be supplied privately or imported while Lumigan is the common therapeutic brand for glaucoma and Careprost is a widely distributed generic ophthalmic solution commonly imported for eyelash enhancement.
• ATC Code: S01EE03.
• Forms & Dosages: Ophthalmic solution 0.03% w/v in 3 mL dropper vials for glaucoma, ocular hypertension and eyelash enhancement.
• Manufacturers In Australia: not specified; notable international manufacturer supplying common generic Careprost is Sun Pharmaceutical Industries Ltd.
• Registration Status In Australia: not specified; bimatoprost products are registered in many jurisdictions globally, with therapeutic glaucoma and cosmetic eyelash approvals varying by country and brand.
• OTC / Rx Classification: Prescription-only in most major jurisdictions; online vendors sometimes offer Careprost without a prescription but this bypasses regulatory channels.

Latest Research Highlights

Worried about whether bimatoprost works for lashes and glaucoma?

International randomised trials of Latisse showed meaningful increases in eyelash length, thickness and darkness by 12–16 weeks.

Clinical glaucoma studies support once-daily evening dosing of bimatoprost 0.03% for sustained intraocular pressure reduction when used long term.

Australian pharmacovigilance and TGA commentary are broadly consistent with global safety signals regarding very common conjunctival hyperaemia and occasional eyelid skin darkening.

Emerging 2022–24 observational reports raise awareness of off‑label cosmetic use risks such as local skin hyperpigmentation and undesired periorbital hair growth.

Adherence studies in chronic glaucoma populations note better pressure control when pharmacists or clinicians support regular follow up and counselling.

Summary Table — Efficacy Endpoints

Summary Table — Safety Frequency & Severity

Clinical Effectiveness In Australia

Are Australian results similar to international trials?

Clinical effectiveness in Australia mirrors international trial outcomes for both glaucoma and eyelash enhancement, with local practice shaped by regulators and funders.

The TGA evaluates safety and registration, while PBS listings for other prostaglandin analogues influence prescribing choices for glaucoma.

Bimatoprost 0.03% once nightly provides reliable IOP reduction comparable to other prostaglandin analogues when adherence is good.

Australian clinic audits show good pressure control when pharmacist counselling and telehealth follow up support adherence.

For cosmetic eyelash use, supply is usually via private prescription or importation, and PBS does not subsidise this indication.

Data Highlights

• TGA Vs PBS Roles: TGA = safety and registration; PBS = subsidy and access influence.
• Clinical Endpoints To Monitor: IOP reduction, visual field stability, ocular surface symptoms.

Indications & Expanded Uses

Can bimatoprost be used for anything beyond glaucoma?

TGA-approved use in Australia principally covers ophthalmic treatment of glaucoma and ocular hypertension.

Cosmetic eyelash growth with branded Latisse is marketed in other jurisdictions and may be accessed privately or imported into Australia.

Off‑label uses include eyebrow and eyelash enhancement with ophthalmic 0.03% solution such as Careprost, and investigational uses for trichiasis or lash hypotrichosis.

Clinicians should document informed consent for off‑label cosmetic use and explain that benefits require ongoing use to persist.

Effects typically appear between 8 and 16 weeks and reverse gradually after stopping.

Approved Vs Off‑Label

• Approved: Glaucoma and ocular hypertension (ophthalmic administration).
• Off‑Label: Eyelash/eyebrow cosmetic enhancement with ophthalmic 0.03% solutions.

Consent Checklist For Off‑Label Cosmetic Use

• Confirm prescription-only status and explain supply route.
• Discuss time to effect (8–16 weeks) and need for maintenance.
• Explain common and rare adverse effects including potential permanent iris pigmentation.
• Document patient agreement and follow-up plan.

Composition & Brand Landscape

Which brands contain bimatoprost and who supplies them?

The active ingredient is bimatoprost (INN), a prostaglandin analogue assigned ATC S01EE03.

Common global brands include Latisse (cosmetic), Lumigan (glaucoma) and Careprost (generic ophthalmic solution in 3 mL, 0.03% v/v packaging).

Careprost is widely distributed via international e‑shops and originates from manufacturers such as Sun Pharmaceutical Industries Ltd.

In Australia, therapeutic glaucoma brands are typically sourced through registered suppliers, while cosmetic-branded Latisse may be available only through private clinics or import channels.

Brand Comparison Table

Pharmacists and consumers in Australia commonly compare generics and branded options on cost and PBS eligibility.

Contraindications & Special Precautions

Who should not use bimatoprost or who needs close monitoring?

Absolute contraindication is known hypersensitivity to bimatoprost or any formulation excipient.

Relative concerns include history of intraocular inflammation such as uveitis and aphakia or pseudophakia because of macular oedema risk.

Pregnancy and breastfeeding are cautioned against due to limited safety data.

Immunosuppressed patients or those at risk of ocular infection deserve careful monitoring.

Elderly patients need routine monitoring for ocular surface and systemic tolerability.

Indigenous and remote populations require culturally safe counselling about pigmentation risks and follow-up access.

Screening Checklist

• Check pregnancy or breastfeeding status.
• Ask about recent eye surgery or history of uveitis.
• Confirm contact lens use and occupational visual needs.
• Advise on TGA adverse-event reporting pathways for any suspected reactions.

Dosage Guidelines

How should bimatoprost be dosed for eyes and lashes?

Glaucoma regimen: instil one drop of bimatoprost 0.03% into the affected eye(s) once daily in the evening.

Cosmetic eyelash regimen: apply one drop with the supplied applicator to the upper eyelid margin nightly and avoid lower lashes.

Expect visible lash changes from about 8 weeks and full effects by 12–16 weeks, with ongoing application required to maintain results.

Children: not recommended due to insufficient safety data.

Elderly: no routine dose adjustment but monitor for ocular surface effects.

Contact lens users must remove lenses before application and wait at least 15 minutes before reinsertion.

Quick Dosing Steps

1. For glaucoma: one drop in affected eye(s) every evening.
2. For lashes: use the applicator to apply one drop to the upper lid margin nightly.
3. If a dose is missed, apply when remembered but do not double dose.

Interactions Overview

Will bimatoprost interact with other medicines or lifestyle factors?

Systemic pharmacokinetic interactions are limited because topical ophthalmic bimatoprost has minimal systemic absorption.

Screen for concurrent ocular hypotensive agents to avoid additive lowering of intraocular pressure.

Alcohol or coffee have no direct interaction, though alcohol can worsen ocular redness or dryness.

Systemic beta‑blockers combined with topical ocular beta‑blockers can increase systemic effects; monitor cardiovascular signs if relevant.

Concurrent topical ocular products with preservatives can increase ocular surface irritation.

Interaction Table

In Australian practice use My Health Record and pharmacist review at major chains for medication reconciliation.

Cultural Perceptions & Patient Habits

What do Australians think about eyelash serums and bimatoprost?

Australian consumers are price-sensitive and tend to trust their local pharmacy for advice and product comparisons.

Careprost and other bimatoprost products are commonly discussed on social media and beauty forums with many anecdotal reports of positive results balanced by concerns about pigmentation and product provenance.

Rural and remote patients face access barriers including fewer specialists and longer wait times, often turning to telehealth or pharmacist advice.

Indigenous health services emphasise culturally safe communication about the potential for permanent pigmentation changes.

Telehealth-enabled prescriptions have increased access but also raise concerns about unsupervised purchases from overseas e‑shops.

Rural Vs Urban Access

Availability & Pricing Patterns

Where can Australians buy bimatoprost and what does it cost?

Prescription bimatoprost for glaucoma is supplied via community pharmacies such as Chemist Warehouse, Priceline and TerryWhite Chemmart and may be influenced by PBS listings for prostaglandin analogues.

Cosmetic eyelash formulations are not PBS-subsidised and are commonly obtained privately or imported; Careprost 3 mL vials are widely available through international online sellers.

Private pricing varies between retail pharmacies and online sellers, and some consumers import Careprost from overseas, which bypasses regulated Australian supply chains.

In our online pharmacy, latisse is available without a prescription, with discreet delivery to Australia in 5-14 days.

Pharmacists should advise on legal and regulatory risks when buying from non‑Australian suppliers and on appropriate storage and sterility concerns.

Pricing Pattern Notes

• PBS subsidises some prostaglandin analogues but not cosmetic indications.
• Generics may be cheaper than branded products but check source and sterility.

Comparable Medicines And Preferences

What are the alternatives to bimatoprost in Australia?

Comparable prostaglandin analogues include latanoprost, travoprost and tafluprost, each with small differences in tolerability and preservative content.

Latanoprost is commonly PBS-listed for glaucoma and often drives prescribing decisions because of subsidy and cost.

For eyelash enhancement, Latisse is the branded comparator while generics such as Careprost are commonly used off‑label.

Clinicians balance efficacy, side-effect profile, patient preference and cost when choosing between agents.

Pros/Cons Checklist

• Bimatoprost: Strong eyelash effect; risk of pigmentation changes.
• Latanoprost: Widely PBS-subsidised for glaucoma; different tolerability profile.

Comparison Table

FAQ — Common Australian Patient Questions

What do patients commonly ask about bimatoprost?

1. Is bimatoprost prescription-only in Australia? Yes, ophthalmic bimatoprost is prescription-only; cosmetic uses usually require clinician oversight and private purchase.
2. Will eyelash darkening or iris colour change be permanent? Lash darkening and increased growth often reverse after stopping; iris colour change is rare but can be permanent.
3. Can I use Careprost bought online from overseas? You may legally import limited personal supply, but quality and sterility cannot be guaranteed; consult your pharmacist or prescriber.
4. How long before I see eyelash results? Expect initial changes by about 8 weeks and full effect by 12–16 weeks; continued use is needed to maintain results.

Guidelines For Proper Use & Pharmacy Counselling

How should pharmacists counsel patients starting bimatoprost?

Explain correct application using the supplied applicator only on the upper eyelid margin and avoiding spread beyond the target area.

Advise contact lens wearers to remove lenses before application and to wait at least 15 minutes before reinserting them.

For glaucoma patients emphasise once‑daily evening dosing and the importance of regular IOP monitoring.

Explain expected adverse effects versus serious signs that require urgent review, such as marked vision change or severe irritation.

Advise on storage: keep at room temperature, protect from light and moisture, and use within four weeks of opening.

Pharmacy Counselling Script (Stepwise)

1. Confirm indication and explain single nightly dosing for either glaucoma or eyelash use.
2. Demonstrate applicator technique for cosmetic use or drop instillation for glaucoma.
3. Discuss common side effects and when to stop and seek care.
4. Arrange follow-up, document counselling and report adverse events to the TGA if needed.

Expected Vs Serious Adverse Effects

• Expected: Redness, local irritation, increased lash growth or darkening, eyelid skin darkening.
• Serious: Sudden vision changes, severe eye pain, signs of infection or suspected iris pigmentation change — seek urgent review.

Delivery Across Australia